Clinical Trial: Beta-3 Enhanced Autonomic Therapy for POTS

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07585513) titled 'Beta-3 Enhanced Autonomic Therapy for POTS' on April 30.

Brief Summary: The study will test the hypothesis that mirabegron is more effective than a placebo in alleviating postural orthostatic tachycardia (POTS) symptoms.

Study Start Date: May, 2026

Study Type: INTERVENTIONAL

Condition: Postural Orthostatic Tachycardia Syndrome (POTS)

Intervention: DRUG: Mirabegron

This is a randomized placebo controlled double blind trial comparing mirabegron with placebo in treating POTS

DRUG: Placebo

Matching placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Cedars-Sinai Medical Center

Information provided by (Responsible Party): ...